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 Multidrug-resistant tuberculosis (MDR-TB) is on the increase, with several Eastern European 
countries having a prevalence of more 
than ten percent [1]. This resistance 
means that patients may not be cured 
with standard regimens even if they 
adhere well to treatment. An MDR-TB 
programme requires advanced medical 
care, infection control measures, 
counselling, and good follow-up, as one 
centre in the Philippines reports in a 
study published in  PLoS Medicine [2].
 The DOTS-Plus (directly observed 
treatment, short-course) project 
is run by the Makati Medical 
Center, supported by the Tropical 
Disease Foundation. The Center 
has exceptional management 
capacity, and was one of the ﬁ rst few 
nongovernmental organizations to 
be a principal recipient of grants 
from the Global Fund to Fight AIDS, 
Tuberculosis and Malaria (known as 
the Global Fund). The Center itself 
provides high-quality tertiary care. 
Within this setting, clinicians from 
the Makati Medical Center used drug 
history and sensitivity testing to provide 
individualised regimens of expensive 
second-line drugs, estimated to cost 
more than US$1,500 per patient. The 
authors report on a cohort of 171 
patients with MDR-TB, of whom 117 
were enrolled and analysed, with 61 
percent cured. Indirect outcome data 
from patients from other countries 
were then combined with local cost 
data to estimate the number of 
premature deaths and secondary cases 
averted in order to provide an estimate 
of the mean cost per disability-adjusted 
life year gained. The 13 authors, 
from the Makati Medical Center, the 
Philippines Department of Health, 
the World Health Organization, and 
the Stanford University School of 
Medicine, conclude that treating MDR-
TB patients is feasible and cost-effective 
in low- and middle-income countries. 
 The World Health Organization 
and other agencies are promoting 
services to treat MDR-TB [3]; the 
Global Fund is waiting in the wings, 
able to fund them. This promotion 
may cause pressure for countries to 
rapidly implement and expand such 
programmes. It is therefore imperative 
that expansion be based on sound 
evidence that such programmes work 
when scaled up. Hence, policy makers 
need to carefully appraise the evidence 
rather than just the conclusions of this 
paper and other papers, and consider 
the following four points. 
 First, this present analysis is not an 
independent evaluation. As is clearly 
stated, the authors include World 
Health Organization staff (who are 
promoting DOTS-Plus) and Tropical 
Disease Foundation staff (who are 
receiving Global Fund money for 
providing services). Further evaluations 
are needed to boost the evidence base. 
 Second, readers need to consider 
whether these specialist medical 
services can actually be provided 
at scale. This paper reports on a 
relatively small programme provided 
under ideal conditions; the operation 
was not intended to be under usual 
programmatic service provision. To 
establish such centres of excellence 
elsewhere in the country, infrastructure 
and staff training costs, not included in 
the cost-effectiveness analysis, would be 
considerable. In the event that decision 
makers do scale up MDR-TB services, 
health policy and systems research will 
be important to systematically identify 
health systems barriers and constraints, 
monitor progress, and draw out lessons 
from such programmes [4].
 Third, policy makers need to take 
into account the potential adverse 
effects of such large investments in 
one aspect of TB control. Human 
resource capacity in the public health 
sector is already stretched: would 
such a programme divert political 
attention, resource allocation, specialist 
medical attention, and public health 
management capacity away from ﬁ rst-
line treatment of tuberculosis—and, 
indeed, other functions of primary 
care? The Stop TB Partnership 
recommends that DOTS-Plus 
programmes should be instituted where 
there are effective DOTS programmes 
in place. DOTS-Plus programmes 
are distinguished from DOTS by the 
provision of additional second-line TB 
drugs, given as individualised treatment 
according to case by case susceptibility, 
or, when diagnostic facilities are fewer, 
as empirical treatment in people 
that have presumed MDR-TB. It is 
paradoxical that it is in areas where 
TB control is poorly implemented 
that the prevalence of MDR-TB is 
likely to rise. Ensuring adherence to 
primary treatment of tuberculosis is 
hard work and needs good health 
service strategy and management. 
Although these aspects may be viewed 
as rather mundane, they are central to 
promoting public health and avoiding 
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the development of drug resistance in 
the ﬁ rst place. 
 Fourth, although the Global Fund can 
provide money for drugs for expensive 
special programmes, these programmes 
establish a highly expensive recurrent 
cost commitment that will go beyond 
the ﬁ ve-year term of the Global Fund 
grant. These cost commitments raise 
questions about the sustainability of 
these programmes. Past experience 
with secondary care in low- and middle-
income countries indicates that these 
costs burgeon, and when money is short 
these medical costs may consume the 
lion’s share of the total TB budget, at 
the expense of primary-care provision.
 This paper reports on a well-run pilot 
study. It is a start, but should not be 
used as the basis for global scaling-up 
of MDR-TB programmes. It highlights 
the need for robust, prospective, and 
independent evaluation of any further 
investment in MDR-TB control, with 
careful attention to the potential 
negative impact on the overall health 
system, particularly primary TB control, 
in terms of investment of time, money, 
and political attention. At the end 
of the day, it is the responsibility of 
national policy makers to maintain 
control of their own health-care system, 
whatever external experts are pushing 
and whatever funding is on offer. These 
responsibilities mean having to balance 
primary care with the need for difﬁ cult 
and expensive treatment for a few but 
increasing number of patients.  
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